Hoffmann-la Roche Inc.

Forma Therapeutics, Inc.

Valo Health, Inc.

Valo Early Discovery, Inc.

Takeda Pharmaceutical Company Limited

F. Hoffmann-la Roche Ag

Steven Gregory Mischke

Hongbin Li

Shawn E R Schiller

Angela V West

Justin Andrew Caravella

David James Richard

Anna M Ericsson

Kin-Chun Thomas Luk

Torsten Herbertz

Bradford Graves

Jennifer R Downing

Shaoqing Chen

Yimin Qian

Stephanos Ioannidis

David Joseph Guerin

Tatiana Shelekhin

David R Lancia, Jr

Kenneth W Bair

Pui Yee Ng

Matthew W Martin

Zhongguo Wang

Kyungjin Kim

Yi Heng Chen

Yan Lou

Stacy W Remiszewski

Peter Michael Wovkulich

Paige Erin Mahaney

Robert Francis Kester

Kang Le

David Robert Bolin

Xin-Jie Chu

Wendy Lea Corbett

Christophe Michoud

Kshitij Chhabilbhai Thakkar

Emily Aijun Liu

Jianping Cai

Hong Wang

Alex J Buckmelter

Jefferson Wright Tilley

Bingsong Han

Alexandre Joseph Buckmelter

Cuixian Liu

Shawn David Erickson

Zhuming Zhang

Ramakanth Sarabu

Robert Alan Goodnow, Jr

Nancy-Ellen Haynes

Nader Fotouhi

Jin-Jun Liu

Norman Kong

Kevin Richard Guertin

Steven Joseph Berthel

Xiaochun Han

Nathan Robert Scott

Joan Heather Hogg

John Anthony Moliterni

Nicholas J S Huby

Francis A Mennona

Apostolos Dermatakis

Kenneth Carey Rupert

Scot Mente

Hongmao Sun

Shoaqing Chen

Shawn ER Schiller

David R Lancia Jr

Jr David R Lancia

Nicholas John Silvester Huby

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).

Inhibiting deubiquitinase USP25 and USP28

The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.

Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

The disclosure relates to USP30 Inhibitor Compounds I, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same. (I) 

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R, R, R, R, R, R, R, X, and n are described herein. 

Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors

The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Protease 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. Chemical entities disclosed herein include compounds of Formula (II): wherein A, R, R, R, R, R, R, R, R, and m are defined herein.

Inhibiting ubiquitin specific peptidase 30

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R, R, R, R, R, R, R, R, X, m, and n are described herein.

Thienopyridine carboxamides as ubiquitin-specific protease inhibitors

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R, R, Rand Rare described in this application, and methods of using said compounds in the treatment of cancer. 

Antiproliferative benzo [B] azepin-2-ones

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer. 

Azaheterocycles as BIR2 and/or BIR3 inhibitors

Growing community of inventors

Florham Park, NJ, United States of America

Steven Gregory Mischke